Studies have shown that active fund managers routinely underperform the S&P500 index*​

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)

CTXR Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
76.40%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
330.80%

CTXR Stock Analysis

CTXR PE Ratio:

CTXR PEG Ratio:

CTXR Forward EPS Growth (12 month): 68.10%

CTXR PS Ratio: 1.2

CTXR PSG Ratio:

CTXR Forward Revenue Growth (12 month): 83.60%

CTXR Articles

No data was found